Abstract
Refractory ventricular tachyarrhythmias are life threatening, especially in patients with stage D heart failure, and left ventricular assist device therapy is virtually the sole option to resolve the fatal conditions in many cases. The Interagency Registry for Mechanically Assisted Circulatory Support defines modifier A as complicating recurrent ventricular tachyarrhythmias. However, the optimal timing to implant a left ventricular assist device remains to be determined in less sick patients with modifier A. We experienced three patients with stage D heart failure with revised modifier A, i.e., at least two appropriate operations of implantable cardiac defibrillators within 2 weeks. Two of them were rescued by extracorporeal left ventricular assist device implantation, but one died because of an electrical storm before left ventricular assist device support was available. We would like to emphasize that we should consider implantable left ventricular assist device therapy as soon as possible for those who are assigned modifier A to prevent sudden arrhythmic death.
Similar content being viewed by others
References
Gomes JA, Mehta D, Ip J, Winters SL, Camunas J, Ergin A, Newhouse TT, Pe E. Predictors of long-term survival in patients with malignant ventricular arrhythmias. Am J Cardiol. 1997;15:1054–60.
Davis JE, Curtis LA, Rashid H. Idiopathic cardiac electrical storm. J Emerg Med. 2009;37:264–8.
Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;20:2140–50.
Kinugawa K. How to treat stage D heart failure? When to implant left ventricular assist devices in the era of continuous flow pumps? Circ J. 2011;75:2038–45.
Stevenson LW, Pagani FD, Young JB, Jessup M, Miller L, Kormos RL, Naftel DC, Ulisney K, Desvigne-Nickens P, Kirklin JK. INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant. 2009;28:535–41.
Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, Long JW, Ascheim DD, Tierney AR, Levitan RG, Watson JT, Meier P, Ronan NS, Shapiro PA, Lazar RM, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;15:1435–43.
Patel P, Williams JG, Brice JH. Sustained ventricular fibrillation in an alert patient: preserved hemodynamics with a left ventricular assist device. Prehosp Emerg Care. 2011;15:533–6.
Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, Ulisney KL, Baldwin JT, Young JB. Third INTERMACS Annual Report: the evolution of destination therapy in the United States. J Heart Lung Transplant. 2011;30:115–23.
Saito S, Matsumiya G, Sakaguchi T, Miyagawa S, Yoshikawa Y, Yamauchi T, Kuratani T, Sawa Y. Risk factor analysis of long-term support with left ventricular assist system. Circ J. 2010;74:715–22.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Imamura, T., Kinugawa, K., Shiga, T. et al. Early decision for a left ventricular assist device implantation is necessary for patients with modifier A. J Artif Organs 15, 301–304 (2012). https://doi.org/10.1007/s10047-012-0645-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10047-012-0645-5